FY2025 · ended Dec 31, 2025 · Revenue $564.17M, +17.0% YoY · Filed Feb 26, 2026
Organogenesis Holdings Inc. (ORGO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $564.2 million and net income of $37.0 million. Free cash flow was -$24.5 million. As of Sep 30, 2026 it held $21.3 million in cash and investments and $35.2 million in total debt.
Revenue (TTM)
$352.05M
-24.3% vs year-ago TTM
Net income (TTM)
$-135.35M
-13567.9% vs year-ago TTM
Operating cash flow (TTM)
$10.30M
+126.6% vs year-ago TTM
Free cash flow (TTM)
$-64,000
+99.9% vs year-ago TTM
EPS (TTM)
$-1.16
-14856.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
128.64M
+1.4% vs prior year
Net cash
$-13.87M
as of Sep 30, 2026
Operating margin
-24.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORGO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Canton, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1661181
- Former names
- Avista Healthcare Public Acquisition Corp. (until Dec 10, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | $467.4M |
| Operating income | $44.7M | -$1.3M | $12.5M | $22.3M | $72.2M |
| Net income | $37.0M | $861,000 | $4.9M | $15.5M | $94.2M |
| Diluted EPS | $0.15 | -$0.01 | $0.04 | $0.12 | $0.70 |
| Operating cash flow | -$10.3M | $14.2M | $30.9M | $24.9M | $62.0M |
| Free cash flow | -$24.5M | $4.2M | $6.6M | -$9.0M | $30.8M |
| Total assets | $598.7M | $497.9M | $460.0M | $449.4M | $443.3M |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $201.9M |
| Stockholders' equity | $300.1M | $262.9M | $278.7M | $265.7M | $241.3M |
| Cash and investments | $93.7M | $135.6M | $103.8M | $102.5M | $113.9M |
| Total debt | $82.1M | $140.2M | $119.7M | $124.3M | $132.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2026 | Jun 15, 2026 |
All 673 Organogenesis Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.